ArticleThe Journal of antimicrobial chemotherapy2025
Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single point mutations in global regulatory genes restore cephalosporin resistance in a low-MICAntimicrobial agents and chemotherapy · 2026Article
- Congenital hepatic fibrosis and related ciliopathies across the life course: current management, disease burden, and unmet needs in the era of genomic diagnosis and translational therapeutics.Frontiers in pediatrics · 2026Review
- Anionic Boron-Cluster BODIPY Conjugates As Promising Photosensitizers for Targeted Antimicrobial Photodynamic Therapy.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEnterococcus faecium, a significant hospital associated pathogen, poses substantial treatment challenges. While combinations of ampicillin with cephalosporins are first-line therapies to treat Enterococcus faecalis high-mortality-rates infections, their efficacy against ampicillin-susceptible E. faecium (ASEfm) is less clear. This study evaluates the effectiveness of combining ampicillin with ceftriaxone or ceftaroline against ASEfm strains.
methodsTen ASEfm bloodstream isolates from complicated infections were analyzed. Susceptibility to several antibiotics, including ceftriaxone, ceftaroline, and cefotaxime, was determined using standard methods. Time-kill assays were conducted to assess the synergistic and additive effects of ampicillin in combination with ceftriaxone or ceftaroline.
resultsTime-kill studies revealed that ampicillin combined with ceftaroline demonstrated synergistic and/or additive effects in 7 out of 10 strains analyzed. In contrast, ampicillin combined with ceftriaxone showed less pronounced synergy, with only 3 out of 10 strains exhibiting synergistic and/or additive effects.
conclusionsOur findings indicate that ampicillin combined with ceftaroline, or ceftriaxone provides synergistic activity against some but not all ASEfm clinical isolates. The observed synergy suggests that these combinations could offer a potential therapeutic option for challenging ASEfm infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.